Navigation Links
Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
Date:12/12/2011

LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that its investigational product candidate MYDICAR® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of advanced heart failure.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR® to become an important treatment for patients with chronic, advanced heart failure," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp.  Dr. Zsebo continued, "Today we are pleased that the FDA recognizes the potential benefit of MYDICAR® to address the enormous unmet medical need for additional therapeutics to treat advanced heart failure patients by granting the program Fast Track Status."

About the CUPID Trial

The previously announced results of the phase 2 CUPID Trial met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as death, need for left ventricular assist device (LVAD) or cardiac transplant, episodes of worsening heart failure and number of heart failure-related hospitalizations.

The mean duration of hospitalization in the MYDICAR® high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially n
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
2. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
3. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
4. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
5. Leatt Corporation Announces 2011 Annual Shareholders Meeting
6. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
7. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
8. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
9. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2012
10. Ansell Limited Acquires a Minority Share in Yulex Corporation
11. The Female Health Companys Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Calif. , Aug. 20, 2014 ... will be using advanced, ventilator technology from Covidien ... to care for patients. The ... more naturally, compared to conventional mechanical ventilation, and ... soon as possible. Patients on mechanical ventilation are ...
(Date:8/20/2014)... Aug. 20, 2014 Children aren,t the ... vaccinations to help prevent disease. The Centers for ... all adults, but currently, many adults are not ... National Immunization Awareness Month, and the American Lung ... especially those with lung disease, to talk with ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
(Date:8/20/2014)... of chronic users of codeine-containing cough syrups (CCS) ... white matter and associates these changes with increased ... diffusuion tensor imaging (DTI) (an MR imaging technique), ... matter integrity of chronic CCS users. Deficits were ... the inferior fronto-occipital fasciculus, which other studies have ...
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... exercise may help older women avoid a condition that causes ... active postmenopausal women had a 10 percent lower risk of ... researchers report in the Aug. 20 issue of the ... enjoyed this protection against the heart rhythm disorder even if ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2
... backboned animals, but recent study has shown that things ... of their skeletal development. These findings will be published ... scientists were able to find the very same protein, ... which is also found in all vertebrates with backbones ...
... that babies breastfed for six months have reduced respiratory ... was conducted by investigators at UC Davis Children's Hospital, ... Pediatrics, Center for Child Health Research. ,In ... Davis Children's Hospital, lead author, "We found that babies ...
... by the Canadian snacks company Frito Lay Canada has launched ... South Asians. ,40 chip flavours created and tested ... and wasabi for test marketing. Stores were stocking these chops ... South Asians annually spends $12.6 billion on retail goods and ...
... technique to test and identify 'dead regions' in the ... children is being developed by Karolina Kluk, a Cambridge ... for development of individualized hearing aids for children. ... patients regarding their sensitivity to a range of tones ...
... skin cancer is the most common tumor to be diagnosed. It ... University Hospital of Navarra. // Sadly, the incidence melanoma has been ... killer of women aged between 19 and 50 years. In the ... 9000 in just 10 years. ,Two main factors regarded ...
... use birth control patch are twice as likely to develop clots ... found. Recently, another study conducted on similar grounds // has revealed ... sides, women who use the patch have been urged to discus ... ,Women who use the patch may be at an increased ...
Cached Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:New Technique Could Revolutionize Melanoma Diagnosis and Treatment 2
... Cascade M-4 is a manual ... all routine clotting assays - PTs, ... Designed for easy, inexpensive, low-volume testing, ... but big on features, offering time ...
... STA is a fully-automated, coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
... ACL Advance can reduce costs ... lab. With its superior ACL ... easy to use coagulation analyzer ... Plus, the protective transparent cover ...
... Pro Professional Hemoglobin Testing System consists of ... strips, used in measuring total hemoglobin, from ... Pro provides the precision, accuracy and cost ... Pro Professional Hemoglobin Testing System is portable ...
Medicine Products: